ICU Medical CFO sells 6,381 shares at $175

Q: What insider transaction did ICUI disclose in this Form 4?

ICU Medical disclosed that its CFO, Brian Michael Bonnell, sold 6,381 shares of common stock on September 1, 2026, in a transaction reported with code “S,” indicating a sale in an open market or private transaction at $175.00 per share.

Q: What was the sale price in the ICUI CFO’s Form 4 transaction?

The Form 4 reports that all 6,381 shares were sold at $175.00 per share. A footnote states that all shares sold were sold at the exact price disclosed, confirming that $175.00 is the per-share sale price for the entire transaction.

Q: What type of ICUI security was involved in this Form 4 transaction?

The transaction involved Common Stock of ICU Medical. The Form 4 lists the security title as common stock and reports a single non-derivative transaction with no associated derivative securities in the derivative holdings summary.

After selling 6,381 shares on Sept. 1 at $175, CFO Brian Michael Bonnell still directly holds 56,062 shares.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold 6,381 shares of common stock on September 1, 2026, at $175.00 per share in an open-market or private transaction. After this sale, he directly holds 56,062 shares. The sale was described as involving restricted award shares and was effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, with all shares sold at the exact disclosed price.

Insider Trade Summary 10b5-1

Net Seller: 6,381 shares

Net Sell 1 txn

Insider Bonnell Brian Michael

Role Chief Financial Officer

Sold 6,381 shs ($1.12M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	6,381	$175.00	$1.12M

Holdings After Transaction: Common Stock — 56,062 shares (Direct)

Footnotes (2)

F1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.
F2. All shares sold were sold at the exact price disclosed.

Key Figures

Shares sold: 6,381 shares Sale price per share: $175.00 per share Shares owned after transaction: 56,062 shares +2 more

5 metrics

Shares sold 6,381 shares Common stock sale on September 1, 2026

Sale price per share $175.00 per share Price for all shares sold in the September 1, 2026 transaction

Shares owned after transaction 56,062 shares Direct beneficial ownership following the reported sale

Net shares sold 6,381 shares Net sell direction in transaction summary

Rule 10b5-1 plan adoption date June 1, 2026 Date the CFO adopted the trading plan used for the sale

Key Terms

Rule 10b5-1 trading plan, restricted award, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted award financial

"The restricted award sales reported in this Form 4 were effected"

open market or private transaction financial

"transaction code description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ICUI disclose in this Form 4?

ICU Medical disclosed that its CFO, Brian Michael Bonnell, sold 6,381 shares of common stock on September 1, 2026, in a transaction reported with code “S,” indicating a sale in an open market or private transaction at $175.00 per share.

How many ICUI shares does the CFO hold after this transaction?

After the reported sale, CFO Brian Michael Bonnell directly holds 56,062 shares of ICU Medical common stock. This post-transaction holding figure is disclosed in the Form 4 as the total shares beneficially owned following the transaction.

What was the sale price in the ICUI CFO’s Form 4 transaction?

The Form 4 reports that all 6,381 shares were sold at $175.00 per share. A footnote states that all shares sold were sold at the exact price disclosed, confirming that $175.00 is the per-share sale price for the entire transaction.

Was the ICUI CFO’s stock sale under a Rule 10b5-1 trading plan?

Yes. A footnote explains that the restricted award sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. The filing’s Rule 10b5-1 checkbox is also marked as affirmed.

What type of ICUI security was involved in this Form 4 transaction?

The transaction involved Common Stock of ICU Medical. The Form 4 lists the security title as common stock and reports a single non-derivative transaction with no associated derivative securities in the derivative holdings summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/01/2026 - 05:22 PM EDT Accepted by SEC EDGAR 09/01/2026 - 05:21 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonnell Brian Michael

(Last)

(First)

(Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE

CALIFORNIA

92673

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2026		S		6,381⁽¹⁾	D	$175⁽²⁾	56,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

2. All shares sold were sold at the exact price disclosed.

	By: Paula Darbyshire, Attorney-in-Fact For: Brian Bonnell	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR